TechMARK movers: Oxford Bio jumps on trial

15th Oct 2009 12:35

Oxford Biomedica doubled at one stage Thursday after it said patients taking part in a Phase I/II trial of its Parkinson's disease drug ProSavin have shown further improvement in motor function.A six-month assessment at the second dose level has been completed and boss John Dawson says there's now an opportunity to start increasing the dosage, which could be even more effective and speed up development."The preclinical proof-of-concept studies together with clinical data from the first two dose levels in the Phase I/II study suggest that ProSavin may provide sustained and meaningful benefit to patients and could reduce or eliminate the debilitating complications associated with oral dopamine replacement therapy," said principal investigator professor Stéphane Palfi of the Henri Mondor Hospital in Paris."In the initial indication of moderate to late-stage Parkinson's disease, ProSavin potentially offers significant advantages to the current alternatives of Deep Brain Stimulation or mechanical delivery of continuous dopamine."Morse also advanced after the IT consultant swung to a quarterly operating profit of £1.9m compared with a loss of £0.5m last year.FTSE TechMARK - RisersOxford Biomedica (OXB) 17.75p +65.12%Morse (MOR) 38.75p +8.39%NXT (NTX) 15.25p +7.02%Torotrak (TRK) 28.00p +6.67%Phytopharm (PYM) 28.50p +6.54%Sepura (SEPU) 47.50p +5.56%Phoenix IT Group (PNX) 239.00p +3.91%Anite Group (AIE) 35.00p +2.94%Kofax (KFX) 170.00p +2.72%Psion (PON) 118.75p +1.93%FTSE TechMARK - FallersRM Group (RM.) 158.00p -2.02%Alterian (ALN) 188.00p -1.70%Consort Medical (CSRT) 414.00p -1.66%Filtronic (FTC) 36.00p -1.37%Trafficmaster (TFC) 41.00p -1.20%Emblaze (BLZ) 42.00p -1.18%KCOM Group (KCOM) 42.25p -1.17%Alphameric (ALM) 35.00p -0.71%Antisoma (ASM) 36.75p -0.68%